KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Research & Development: 2014-2024

Historic Research & Development for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to $320.7 million.

  • CRISPR Therapeutics AG's Research & Development fell 28.31% to $58.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $283.4 million, marking a year-over-year decrease of 15.05%. This contributed to the annual value of $320.7 million for FY2024, which is 17.21% down from last year.
  • CRISPR Therapeutics AG's Research & Development amounted to $320.7 million in FY2024, which was down 17.21% from $387.3 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Research & Development registered a high of $461.6 million during FY2022, and its lowest value of $221.4 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $387.3 million (2023), whereas its average is $389.9 million.
  • In the last 5 years, CRISPR Therapeutics AG's Research & Development skyrocketed by 53.84% in 2021 and then fell by 17.21% in 2024.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Research & Development stood at $221.4 million in 2020, then surged by 53.84% to $340.6 million in 2021, then skyrocketed by 35.55% to $461.6 million in 2022, then declined by 16.10% to $387.3 million in 2023, then dropped by 17.21% to $320.7 million in 2024.